August 29, 2011
Xalkori Approved for Advanced Lung CancerXalkori (crizotinib) and a
companion diagnostic test have been approved by the U.S. Food and
Drug Administration to treat advanced non-small cell lung cancer
(NSCLC) with a certain genetic abnormality, the agency said in a
news release.